8-K: BioAffinity Technologies Secures Flexible At-The-Market Equity Offering for Up to $30 Million, Currently Limited to $5.8 Million

BioAffinity Technologies, Inc. has entered into an At-The-Market (ATM) Issuance Sales Agreement with WallachBeth Capital LLC to sell common stock, providing a flexible capital raising mechanism with a potential aggregate value of up to $30 million, though currently limited to $5.8 million under SEC rules.

Summary

• BioAffinity Technologies, Inc. (BIAF) entered into an At-The-Market (ATM) Issuance Sales Agreement with WallachBeth Capital LLC on May 22, 2025.
• The agreement allows the Company to sell its common stock from time to time in an at-the-market offering program.
• The maximum aggregate market value of shares eligible for sale under the ATM Agreement is $30,000,000, referred to as the 'Maximum Amount'.
• However, the current aggregate market value of shares eligible for sale under the ATM Prospectus Supplement is $5,801,000, based on the limitations of General Instruction I.B.6 of Form S-3.
• Sales will be made through WallachBeth Capital LLC as the sales agent, using methods permitted by law for at-the-market offerings, including sales on the Nasdaq Capital Market or other trading markets, or directly to WallachBeth as principal.
• The Company retains control over the sales parameters, including the number of shares, sales period, daily limits, and minimum price.
• WallachBeth Capital LLC will receive a commission of 3.0% of the gross sales price for all shares sold through the agreement.
• The Company is not obligated to sell any shares and can suspend or terminate the offering at any time.
• The ATM Agreement will terminate upon the sale of all shares or automatically on its two-year anniversary, or can be terminated by either party with 10 days' written notice.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it introduces potential dilution, securing a flexible capital raising mechanism like an ATM is generally a positive strategic move for a company, especially in the biotech sector, as it provides access to funding for future operations and growth without immediate pressure or a large, single offering. The current limitation on the amount is a minor dampener but not a negative for the agreement itself.

Positives

• The ATM agreement provides BioAffinity Technologies with a flexible and efficient mechanism to raise capital as needed, without the complexities and costs associated with traditional underwritten offerings.
• The Company maintains control over the timing and pricing of share sales, allowing it to respond to market conditions and capital requirements.
• The potential to raise up to $30,000,000 in the aggregate provides significant financial flexibility for future operations and strategic initiatives.
• The agreement is supported by a shelf registration statement on Form S-3, indicating the Company's eligibility for streamlined offerings.

Negatives

• The offering could lead to dilution for existing shareholders as new common stock is issued.
• The current limitation of $5,801,000 on eligible sales, based on Form S-3 rules, means the Company cannot immediately access the full $30,000,000 potential of the agreement.
• The 3.0% commission to the sales agent represents a cost of capital, though typical for ATM programs.

Risks

• Potential dilution of existing shareholders' equity due to the issuance of new common stock.
• Downward pressure on the Company's stock price if a significant number of shares are sold into the market.
• The Company's ability to raise capital is subject to market conditions and the prevailing stock price, which may not always be favorable.
• The ATM Agreement can be terminated by the agent if a 'Material Adverse Effect' occurs in the Company or if there are material adverse changes in financial markets, potentially limiting access to capital when most needed.
• Compliance with SEC and Nasdaq listing requirements is ongoing, and failure to comply could impact the ability to sell shares.

Future Outlook

The ATM agreement provides BioAffinity Technologies with a flexible financing tool to raise capital on an 'as-needed' basis over the next two years, or until the maximum amount of shares are sold. This allows the Company to fund ongoing operations, research and development, or other strategic initiatives as opportunities arise, subject to market conditions and the Company's discretion.

Management Comments

• Maria Zannes, President and Chief Executive Officer, signed the Form 8-K on behalf of BioAffinity Technologies, Inc., indicating management's approval and execution of the ATM Agreement.

Industry Context

At-The-Market (ATM) offerings are a common and increasingly popular financing strategy for publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, which often require continuous access to capital for research, clinical trials, and commercialization efforts. This method provides greater flexibility compared to traditional follow-on offerings, allowing companies to raise capital incrementally, reduce market impact, and potentially achieve better average pricing over time. It reflects a strategic approach to maintaining liquidity and funding growth without committing to a large, single capital raise.

Comparison to Industry Standards

• ATM offerings are a standard financing tool for small to mid-cap biotech companies, providing a cost-effective and flexible alternative to traditional equity raises.
• The 3.0% commission rate for the sales agent is within the typical range for ATM agreements, which generally fall between 1% and 5% depending on the size and complexity of the offering.
• The use of a Form S-3 shelf registration statement is standard practice for companies that meet the eligibility requirements, enabling efficient and rapid access to capital markets.
• The structure, including the Company's control over sales parameters and the agent's 'commercially reasonable efforts' clause, aligns with common industry practices for such agreements.

Legal Proceedings

• The Company represents that, except as set forth in the Registration Statement or the Prospectus, there are no legal, governmental, or regulatory actions, suits, or proceedings pending or threatened that would reasonably be expected to have a Material Adverse Effect or materially affect the Company's ability to perform its obligations under the agreement.

Stakeholder Impact

• **Shareholders**: Potential for dilution as new shares are issued, which could impact earnings per share and share price. However, the capital raised can fund growth initiatives that may ultimately benefit shareholders.
• **Company**: Gains flexible access to capital for operational needs, research and development, and strategic growth, enhancing financial stability and strategic optionality.
• **Creditors**: Improved liquidity and financial health from capital raises could reduce credit risk.
• **Employees**: Continued funding for company operations may provide job security and opportunities for growth.

Next Steps

• The Company may, at its discretion, issue Placement Notices to WallachBeth Capital LLC to initiate sales of common stock under the ATM Agreement.
• WallachBeth Capital LLC will use commercially reasonable efforts to sell the Placement Shares in accordance with the Company's instructions.
• The Company will continue to comply with SEC reporting requirements and maintain its Nasdaq listing for the common stock.

Key Dates

Recommendation

Keywords

At-The-Market, ATM, Equity Offering, Capital Raise, Common Stock, Dilution, SEC Filing, Form 8-K, WallachBeth Capital, Nasdaq, Shelf Registration, Public Offering, Financing, BIOAFFINITY TECHNOLOGIES